PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 20, 2026Frontiers in Immunology0 citationsOpen Access

Evaluation of Prognostic Scores in NSCLC Patients Undergoing Chemoimmunotherapy

Evaluation of six clinical prognostic scores in NSCLC patients undergoing first line chemoimmunotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJiaqi SunDLDan LiJLJiayin Liu

Discussion

Loading...

Member takes

Overview

An evaluation of six prognostic scores predicts outcomes in NSCLC patients, suggesting their clinical utility.

Key Points

  • This research aims to evaluate the effectiveness of six prognostic scoring systems for predicting outcomes in NSCLC patients undergoing first-line chemoimmunotherapy.
  • NSCLC patients receiving first-line chemoimmunotherapy were included.
  • Six prognostic scores (RMH, MDACC, MDACC+NLR, MDA-ICI, LIPI, GRIm) were assessed.
  • Survival curves generated using the Kaplan–Meier method.
  • Cox proportional hazards regression model was used for univariate and multivariate analyses.
  • C-index and time-dependent AUC calculated for predictive performance comparison.
  • Median overall survival for patients was 36.5 months.
  • Median progression-free survival was 14.5 months.
  • RMH achieved the highest C-indices for overall survival (0.672) and progression-free survival (0.652).
  • MDACC maintained a statistically significant association with overall survival after FDR correction.
  • MDACC+NLR showed marginal significance for progression-free survival after FDR correction.

Cite This Study

Sun et al. (2026) studied this question.

synapsesocial.com/papers/6997f984ad1d9b11b3452474https://doi.org/10.3389/fimmu.2026.1695859
View Full Paper
Ask AI
Bookmark
Share